Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1111MR)

This product GTTS-WQ1111MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1111MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10559MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ2451MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ994MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ1988MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ9069MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ3202MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ7328MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ9362MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW